2025
Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus
Xu H, Aparicio C, Wats A, Araujo B, Pitzer V, Warren J, Shapiro E, Niccolai L, Weinberger D, Oliveira C. Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus. JAMA Network Open 2025, 8: e250380. PMID: 40063022, PMCID: PMC11894488, DOI: 10.1001/jamanetworkopen.2025.0380.Peer-Reviewed Original ResearchConceptsRSV-positive casesCase-control studyRSV infectionLRTI-associated hospitalizationsWeeks postimmunizationLong-acting monoclonal antibodiesTest-negative case-control studyClinical settingRespiratory syncytial virusMultivariate logistic regressionYale New Haven Health SystemRSV diseaseEmergency department dataState immunization registryRSV seasonSyncytial virusNirsevimabPolymerase chain reactionClinical trialsLRTIInfantsPotential confoundersMonoclonal antibodiesBroader outcomesDisease severity
2023
Associations between weekly gestational exposure of fine particulate matter, ozone, and nitrogen dioxide and preterm birth in a North Carolina Birth Cohort, 2003–2015
Krajewski A, Luben T, Warren J, Rappazzo K. Associations between weekly gestational exposure of fine particulate matter, ozone, and nitrogen dioxide and preterm birth in a North Carolina Birth Cohort, 2003–2015. Environmental Epidemiology 2023, 7: e278. PMID: 38912391, PMCID: PMC11189686, DOI: 10.1097/ee9.0000000000000278.Peer-Reviewed Original ResearchPreterm birthGestational exposureWeeks of pregnancyRisk of PTBInterquartile range increasePM 2.5 exposurePoisson regression modelsGestational weeksPotential confoundersFine particulate matterAssociation magnitudeRisk differenceNull associationBirth cohortExposure windowsResidential addressesMultipollutant modelsBirthWeeksPositive associationAssociationExposurePM 2.5Regression modelsCensus tracts
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply